Search results
Added:
1 year ago
EuroPCR 24 - In this succinct interview, we are joined by Dr Hans-Josef Feistritzer (University of Leipzig, DE) to discuss the findings of the SOLVE-TAVI Trial.In recent years, trials such as CHOICE, REPRISE III, the SCOPE trial, PORTICO IDE and the SMART trial have privided increasing evidence for direct TACI valve comparisons as device designs improve. TAVI is increasingly performed using local…
View more
Added:
2 months ago
Added:
1 year ago
HFSA Congress 2024 - Dr Mark Ricciardi (NorthShore Cardiovascular Institute, US) joins us to discuss the findings from the EXPANDed real-world clinical trial on mitral transcatheter edge-to-edge repair with the MitraClip System.The study is designed to confirm the safety and performance of the MitraClip NTR and XTR Systems in mTEER procedures. 1000 patients across 60 sites in Europe and the US…
View more
Added:
4 days ago
Added:
11 months ago
EuroPCR 25 - 10-year follow-up findings of DANAMI-3-DEFER show a deferred stenting strategy may reduce HF hospitalisation in ST-elevation myocardial infarction (STEMI) patients.We are joined by Dr Jacob Lønborg (Rigshospitalet, Copenhagen, DK) to discuss key findings from the 10-year follow-up of the DANAMI-3-DEFER (NCT01435408) trial. This randomized controlled trial compared deferred stent…
View more
Balton
Supplier
Added:
11 months ago
Safety and effectiveness outcomes of a 3-in-1 carotid stent delivery system show no major strokes at 30-day and one-year follow ups and significantly low rates of clinically driven target lesion revascularisation at two years.Dr William Gray (Main Line Health, Pennsylvania, US) joins us to discuss the first European presentation of the two-year outcomes from PERFORMANCE II (NCT04201132; Contego…
View more
Added:
1 year ago
EuroPCR 24 - Dr Roxana Mehran (Mount Sinai Hospital, US) outlines the findings of the ABILITY Global Diabetes study onsite at EuroPCR 2024.The ABILITY study (NCT04236609) aimed to evaluate the efficacy and safety of the Abluminus DES+ Sirolimus Eluting Stent System (SES) as compared to the XIENCE Everolimus Eluting Coronary Stent System in diabetic patients eligible for percutaneous coronary…
View more
Added:
1 year ago
ACC 25 - Findings from a stratified study investigating coronary stenting and bleeding risk suggest 3 months are the optimal duration of DAPT after PCI.Dr Hyo-Soo Kim (Seoul National University Hospital, KR) sits down to discuss the first randomized study stratifying patients receiving percutaneous coronary intervention with drug eluting stents according to bleeding risk based on the ARC HBR…
View more
